Avecho Biotechnology Limited

Avecho Biotechnology Limited is a health technology company specializing in the development and commercialization of pharmaceutical and animal health products leveraging its proprietary drug delivery platform. The company’s core innovation is its tocopherol phosphate mixture (TPM) technology, which is designed to enhance the delivery and absorption of active pharmaceutical ingredients across various formulations, including gels, injectables, and patches. Avecho operates through two primary segments: the Production segment, focused on the manufacturing and sale of TPM and Vital ET for both pharmaceutical and cosmetic applications, and the Human Health segment, which oversees the R&D and commercialization of pharmaceutical products for human use, including products addressing pain and dermatological conditions. Additionally, Avecho’s portfolio includes advancements in cannabinoid-based pharmaceuticals, with a cannabidiol TPM soft-gel capsule that has reached Phase III clinical trials for insomnia. The company also develops non-antibiotic feed additives to support livestock health. Founded in 1992 and headquartered in Clayton, Australia, Avecho plays a specialized role within the biotechnology sector, with a focus on drug delivery innovation and both human and animal health markets.